JPRN-UMIN000009144RecruitingPhase 1
Phase I/II study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Cetuximab in patients with kras wild type-unresectable advanced/metastatic colorectal cancer - XELOXIRI+Cetuximab
Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)0 sites31 target enrollmentStarted: October 18, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 31
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Prior severe drug allergy. 2) Synchronous and/or metachronous multiple cancers. 3) Prior chemotherapy with CPT-11,L-OHP, capecitabeine or Cetuximab containing regimen. 4)Surgical procedure within 28 days prior to enrollment. 5) Severe comorbidity - Severe pulmonary dysfunction - Uncontrolled DM - Uncontrolled HT - Severe cardiovascular disease - Cirrhosis and liver failure - Renal failure 6) Sensory neuropathy 7) Severe diarrhea 8) Active infection 9) Symptomatic pleural effusion or ascites 10)Contraindications to CPT-11, L-OHP, capecitabeine or Cetuximab 11) Concerning pregnancy 12) The investigator considers not suitable for the study.
Investigators
Similar Trials
Recruiting
Phase 1
Phase I study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Bevacizumab in patients with unresectable advanced/metastatic colorectal cancerColorectal cancerJPRN-UMIN000005440Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)24
Completed
Phase 1
OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic AdenocarcinomaPancreatic CancerNCT02368860National Cancer Centre, Singapore33
Completed
Phase 1
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMDAge Related Macular DegenerationNCT04993352Shanghai Henlius Biotech20
Unknown
Phase 1
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsFirst-line TreatmentAdvanced Gastric CarcinomaNCT05221775Tianjin Medical University Cancer Institute and Hospital18
Unknown
Phase 2
A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRCUnresectable Metastatic Colorectal CarcinomaNCT04508452First Affiliated Hospital of Zhejiang University91